Month: September 2025

Newsmakers

Worksport (NASDAQ: WKSP) Posts Fourth Consecutive Monthly Sales Record in July 2025; Gross Margin Reaches 31% Target One Quarter Early

September 10, 2025 admin Comments Off on Worksport (NASDAQ: WKSP) Posts Fourth Consecutive Monthly Sales Record in July 2025; Gross Margin Reaches 31% Target One Quarter Early

Company Achieves Consistent Growth With Four Straight Record Months; Gross Margin Expands 2,000+ Basis Points in Three Quarters; Production Hits Strongest Levels to Date West Seneca, New York, Sept. 09, 2025 — Worksport Ltd. (NASDAQ: […]

Newsmakers

Worksport (NASDAQ: WKSP) Posts Q2 2025 Results: Gross Profit Increases 173%, Revenue Jumps 83%, Margin Expands 870 bps, Operating Loss Improves 15% [QoQ].

September 4, 2025 admin Comments Off on Worksport (NASDAQ: WKSP) Posts Q2 2025 Results: Gross Profit Increases 173%, Revenue Jumps 83%, Margin Expands 870 bps, Operating Loss Improves 15% [QoQ].

Company Reaffirms ≥$20 Million 2025 Revenue Target and Highlights Clear Path to Near-Term Operational Cash Flow Positivity West Seneca, New York, Aug. 13, 2025  — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S. based […]

Newsmakers

Hoth Therapeutics’ (NASDAQ: HOTH) Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

September 4, 2025 admin Comments Off on Hoth Therapeutics’ (NASDAQ: HOTH) Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

NEW YORK, Sept. 2, 2025  — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor efficacy, a clean […]